No two patients’ cancers are biologically identical, so it makes sense for a therapy to be created individually for each patient. To that end, Agenus’ “individualized” brain cancer vaccine Prophage Series G-200 has generated positive results in a Phase 2 trial, with more than 90% of patients treated with the vaccine alive at 6 months after surgery.
Prophage Series vaccines are manufactured using the ‘antigenic fingerprint’ of the patient’s tumour following surgical removal, instructing the patient’s immune system to home in on cancer cells bearing this fingerprint.
The Prophage Series G-200 vaccine is being studied in glioblastoma multiforme (GBM), the most common and most aggressive form of primary brain cancer. GBM is often resistant to standard approved therapies, and so patients often face a poor prognosis, with the expected median survival for recurrent GBM patients of 3 to 9 months. In patients who underwent surgical removal of the tumour and then received the vaccine, the median overall survival was approximately 11 months.
In September, Agenus also announced encouraging results from a mid-stage trial with the Prophage Series G-100 vaccine in GBM.
Read the press release >